Emerging concepts for patients with treatment-resistant hypertension

Lim, 2012, A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010, Lancet, 380, 2224, 10.1016/S0140-6736(12)61766-8 White, 2014, Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda MD, U.S.A., October 10, 2013, J Am Soc Hypertens, 8, 743, 10.1016/j.jash.2014.06.005 Mancia, 2013, 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), Eur Heart J, 34, 2159, 10.1093/eurheartj/eht151 Calhoun, 2008, Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research, Hypertension, 51, 1403, 10.1161/HYPERTENSIONAHA.108.189141 Muntner, 2014, Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT), Hypertension, 64, 1012, 10.1161/HYPERTENSIONAHA.114.03850 Sim, 2015, Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension, Kidney Int, 88, 622, 10.1038/ki.2015.142 Taler, 2002, Resistant hypertension: comparing hemodynamic management to specialist care, Hypertension, 39, 982, 10.1161/01.HYP.0000016176.16042.2F Pimenta, 2009, Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial, Hypertension, 54, 475, 10.1161/HYPERTENSIONAHA.109.131235 Agarwal, 2012, Resistant hypertension and the neglected antihypertensive: sodium restriction, Nephrol Dial Transplant, 27, 4041, 10.1093/ndt/gfs384 Dudenbostel, 2015, Refractory hypertension: evidence of heightened sympathetic activity as a cause of antihypertensive treatment failure, Hypertension, 66, 126, 10.1161/HYPERTENSIONAHA.115.05449 Jung, 2013, Resistant hypertension? Assessment of adherence by toxicological urine analysis, J Hypertens, 31, 766, 10.1097/HJH.0b013e32835e2286 Strauch, 2013, Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis, J Hypertens, 31, 2455, 10.1097/HJH.0b013e3283652c61 Rimoldi, 2014, Secondary arterial hypertension: when, who, and how to screen?, Eur Heart J, 35, 1245, 10.1093/eurheartj/eht534 Mancia, 2013, 2013 ESH/ESC guidelines for the management of arterial hypertension, Blood Press, 22, 193, 10.3109/08037051.2013.812549 Tziomalos, 2013, Hydrochlorothiazide vs. chlorthalidone as the optimal diuretic for the management of hypertension, Curr Pharm Des, 19, 3766, 10.2174/13816128113199990315 Dussol, 2005, A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension, Nephrol Dial Transplant, 20, 349, 10.1093/ndt/gfh650 Verdalles, 2015, Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?, Nephrology (Carlton), 20, 567, 10.1111/nep.12475 Liu, 2015, Effect of aldosterone antagonists on blood pressure in patients with resistant hypertension: a meta-analysis, J Hum Hypertens, 29, 159, 10.1038/jhh.2014.64 Calhoun, 2011, Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial, Circulation, 124, 1945, 10.1161/CIRCULATIONAHA.111.029892 Karns, 2013, Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension, J Clin Hypertens (Greenwich), 15, 186, 10.1111/jch.12051 Acelajado, 2012, Refractory hypertension: definition, prevalence, and patient characteristics, J Clin Hypertens (Greenwich), 14, 7, 10.1111/j.1751-7176.2011.00556.x Kjeldsen, 2015, Physician (investigator) inertia in apparent treatment-resistant hypertension - insights from large randomized clinical trials. Lennart Hansson Memorial Lecture, Blood Press, 24, 1, 10.3109/08037051.2014.946787 Spence, 2016, J curve and cuff artefact, and diagnostic inertia in resistant hypertension, Hypertension, 67, 32, 10.1161/HYPERTENSIONAHA.115.06562 Cataliotti, 2012, Sustained blood pressure-lowering actions of subcutaneous B-type natriuretic peptide (nesiritide) in a patient with uncontrolled hypertension, Mayo Clin Proc, 87, 413, 10.1016/j.mayocp.2012.02.003 Kario, 2014, Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study, Hypertension, 63, 698, 10.1161/HYPERTENSIONAHA.113.02002 Akter, 2015, Higher circulatory level of endothelin-1 in hypertensive subjects screened through a cross-sectional study of rural Bangladeshi women, Hypertens Res, 38, 208, 10.1038/hr.2014.160 Weber, 2009, A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial, Lancet, 374, 1423, 10.1016/S0140-6736(09)61500-2 Almeida, 2013, Etamicastat, a novel dopamine beta-hydroxylase inhibitor: tolerability, pharmacokinetics, and pharmacodynamics in patients with hypertension, Clin Ther, 35, 1983, 10.1016/j.clinthera.2013.10.012 Carlsten, 1958, Cardiovascular effects of direct stimulation of the carotid sinus nerve in man, Acta Physiol Scand, 44, 138, 10.1111/j.1748-1716.1958.tb01615.x Scheffers, 2010, Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study, J Am Coll Cardiol, 56, 1254, 10.1016/j.jacc.2010.03.089 Bisognano, 2011, Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial, J Am Coll Cardiol, 58, 765, 10.1016/j.jacc.2011.06.008 Hoppe, 2012, Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial, J Am Soc Hypertens, 6, 270, 10.1016/j.jash.2012.04.004 Krum, 2014, Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 Study, Lancet, 383, 622, 10.1016/S0140-6736(13)62192-3 Esler, 2010, Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial, Lancet, 376, 1903, 10.1016/S0140-6736(10)62039-9 Bhatt, 2014, A controlled trial of renal denervation for resistant hypertension, N Engl J Med, 370, 1393, 10.1056/NEJMoa1402670 Desch, 2015, Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension, Hypertension, 65, 1202, 10.1161/HYPERTENSIONAHA.115.05283 Rosa, 2015, Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 Study, Hypertension, 65, 407, 10.1161/HYPERTENSIONAHA.114.04019 Pekarskiy, 2015, 8b.05: failure of renal denervation in symplicity HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology, J Hypertens, 33, e108, 10.1097/01.hjh.0000467641.39623.fb Azizi, 2015, Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial, Lancet, 385, 1957, 10.1016/S0140-6736(14)61942-5 Bohm, 2015, First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension, Hypertension, 65, 766, 10.1161/HYPERTENSIONAHA.114.05010 Burchell, 2014, Arteriovenous anastomosis: is this the way to control hypertension?, Hypertension, 64, 6, 10.1161/HYPERTENSIONAHA.114.02925 Limberg, 2015, Effect of bilateral carotid body resection on cardiac baroreflex control of blood pressure during hypoglycemia, Hypertension, 65, 1365, 10.1161/HYPERTENSIONAHA.115.05325